Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2007 1
2008 2
2009 3
2010 4
2011 3
2013 1
2015 1
2016 6
2017 3
2018 3
2019 1
2020 5
2021 9
2022 12
2023 10
2024 10
2025 14
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Les journées caribéennes des maladies rares et orphelines 2022.
Bellance R, Antolín Sanféliz I, Duclos S, Guiget-Valard AG, Inamo J, Signaté A, Allard-Saint-Albin O, Cantacouzéne M, Garófalo Gómez N, Sarrazin E. Bellance R, et al. Among authors: inamo j. Med Sci (Paris). 2023 Nov;39 Hors série n° 1:67-71. doi: 10.1051/medsci/2023138. Epub 2023 Nov 17. Med Sci (Paris). 2023. PMID: 37975776 Free article. French. No abstract available.
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Adams D, et al. Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16. Lancet Neurol. 2021. PMID: 33212063 Free article. Clinical Trial.
Impact of Tafamidis on survival in elderly patients: Insights from the Healthcare European Amyloidosis Registry.
Jobbé-Duval A, Kharoubi M, Donal E, Bauer F, Broussier A, Bisson A, Bouchot O, Charron P, Costa J, Courand PY, Dagrenat C, Delelis F, Eicher JC, Fraix A, Gellen B, Gueffet JP, Habib G, Inamo J, Jeanneteau J, Legallois D, Margerit L, Mouhat B, Piriou N, Puscas T, Réant P, Roubille F, Trésorier R, Von Hunolestein JJ, Taieb C, Zaroui A, Lairez O, Damy T. Jobbé-Duval A, et al. Among authors: inamo j. Int J Cardiol. 2025 Oct 15;437:133522. doi: 10.1016/j.ijcard.2025.133522. Epub 2025 Jun 16. Int J Cardiol. 2025. PMID: 40532791 Free article.
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension.
Adams D, Wixner J, Polydefkis M, Berk JL, Conceição IM, Dispenzieri A, Peltier A, Ueda M, Bender S, Capocelli K, Jay PY, Yureneva E, Obici L; patisiran Global OLE study group. Adams D, et al. JAMA Neurol. 2025 Mar 1;82(3):228-236. doi: 10.1001/jamaneurol.2024.4631. JAMA Neurol. 2025. PMID: 39804640 Free PMC article. Clinical Trial.
Defibrillation Testing During Implantation of Subcutaneous Implantable Cardioverter Defibrillators.
Kerkouri F, Eschalier R, Fareh S, Marquié C, Ait Said M, Amara W, Anselme F, Badoz M, Behar N, Bordachar P, El Bouazzaoui R, Champ Rigot L, Chauvin M, Chevalier P, Da Costa A, Defaye P, Deharo JC, Fauchier L, Gandjbakhch E, Gitenay E, Gourraud JB, Guenancia C, de Guillebon M, Guy-Moyat B, Hermida A, Hourdain J, Jacon P, Khattar P, Laredo M, Jesel L, Lellouche N, Leclercq C, Mansourati V, Maury P, Mondoly P, Pasquié JL, Peyrol M, Pierre B, Ploux S, Potelle C, Sadoul N, Sellal JM, Varlet E, Garcia R, Probst V, Boveda S, Marijon E; HONEST Study Investigators. Kerkouri F, et al. J Am Coll Cardiol. 2025 Jul 8;86(1):32-45. doi: 10.1016/j.jacc.2025.04.048. J Am Coll Cardiol. 2025. PMID: 40602942
Clinical outcomes for 2788 patients with transthyretin amyloidosis: Tafamidis meglumine early access program in France.
Lairez O, Réant P, Inamo J, Jeanneteau J, Bauer F, Habib G, Eicher JC, Lequeux B, Legallois D, Josse C, Hippocrate A, Bartoli M, Dubois M, Noirot Cosson C, Squara PA, Fievez S, Quinault A, Rudant J, Kharoubi M, Damy T. Lairez O, et al. Among authors: inamo j. Arch Cardiovasc Dis. 2025 Feb;118(2):123-132. doi: 10.1016/j.acvd.2024.08.006. Epub 2024 Oct 5. Arch Cardiovasc Dis. 2025. PMID: 39426850
Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey.
González-Moreno J, Dispenzieri A, Grogan M, Coelho T, Tournev I, Waddington-Cruz M, Wixner J, Diemberger I, Garcia-Pavia P, Chapman D, Gupta P, Glass O, Amass L; THAOS investigators. González-Moreno J, et al. Cardiol Ther. 2024 Mar;13(1):117-135. doi: 10.1007/s40119-023-00344-3. Epub 2023 Dec 20. Cardiol Ther. 2024. PMID: 38117424 Free PMC article.
78 results